Poorly Differentiated Carcinoma, NOS
Associated Genetic Biomarkers
Poorly differentiated carcinoma, NOSs most frequently harbor alterations in TP53, CDKN2A, KRAS, KMT2D, and ARID1A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in poorly differentiated carcinoma, NOS .
There is 1 clinical trial for poorly differentiated carcinoma, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains poorly differentiated carcinoma, NOS as an inclusion criterion, 1 is phase 2 (1 open).
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.